Newly developed retatrutide, a dual -action medication targeting both GLP-1 and GIP receptors, is generating considerable excitement within the medical community. Initial clinical trials have shown significant losses in physical size and gains in physiological markers for people with obesity . Experts believe this unique approach has the potent… Read More